



INFORMAZIONI PERSONALI

Alessandro Loglio

Data di nascita: 27/10/1986

ISTRUZIONE E FORMAZIONE

5 Luglio 2012 – 11 Luglio 2017

Specializzazione in Gastroenterologia ed Endoscopia Digestiva presso l'Università degli Studi di Milano, con votazione 70/70 con Lode, discutendo la Tesi "Ruolo del dosaggio dell'alfa-fetoproteina nel predire lo sviluppo di epatocarcinoma nei pazienti cirrotici HBV: studio di coorte in 262 soggetti trattati con analoghi nucleos(t)idici per otto anni". Relatore Prof. Maurizio Vecchi, correlatore Prof. Pietro Lampertico

Abilitazione ed
Iscrizione Albo Professionale

1 Marzo 2012; OMCEO di Milano

Ottobre 2005 – 27 Ottobre 2011

Laurea in Medicina e Chirurgia presso l'Università degli Studi di Milano, con votazione 110/110 con Lode, discutendo la Tesi "Progetto CAMELIA: studio della distribuzione del grasso corporeo ed associazione con sindrome metabolica e steatosi epatica in una popolazione del Nord Italia". Relatore Prof. Massimo Zuin, correlatore Prof. Piermaria Battezzati

Luglio 2005

Maturità Scientifica presso "Liceo Lorenzo Federici", Trescore Balneario (BG)

ESPERIENZA FORMATIVA

16 Agosto 2017 ad oggi

Responsabile dell'ambulatorio HBV/HDV, inclusi i pazienti trapiantati di fegato o con epatocarcinoma.

Primo utilizzo in Europa di Bulevirtide/Myrccludex-B ad uso compassionevole per il trattamento della epatite HDV. Membro dell'Hepatitis Delta International Network, con attuale gestione della terapia con Bulevirtide di 22 pazienti.

Gestione (safety/efficacy) delle terapie antivirali con TAF, TDF, ETV, LAM, Interferone, Onafarnib, e dei nuovi RNA-interference nell'ambito di studi clinici.

Principale Sub-investigatore di studi clinici di fase II-III in GCP su HDV e HBV (attualmente 4 in corso).

Partecipazione attiva alle riunioni multidisciplinari con chirurghi trapiantologi e radiologi interventisti sul trattamento dell'epatocarcinoma e l'indicazione ad eventuale trapianto epatico. Valutazione dei pazienti per inserimento in lista OLT.

Guardie divisionali e notturne. Consulenze epatologiche nei reparti.

Attività di ricerca in ambito HBV, HDV, HCC ed ipertensione portale.

Attività di tutoraggio degli Specializzandi afferenti al Centro.

Ambulatorio CBP nel 2018-2019.

*UO Gastroenterologia ed Epatologia, direttore Prof. P. Lampertico
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano*

Luglio 2017 – Agosto 2017
Medico Volontario

Gestione dell'ambulatorio HBV. Ricerca in ambito HBV, HCC ed ipertensione portale. Sub-investigator di studi clinici in GCP.

UO Gastroenterologia ed Epatologia, direttore Prof. P. Lampertico
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano

Attestati acquisiti

- Diploma Nazionale SIUMB di Competenza in Ecografia Clinica – 15 Novembre 2017
- Attestato di utilizzo del FibroScan – 25 Settembre 2019
- Ultimo “GCP Training Certificate” acquisito il 23 Ottobre 2018
- Basic Life Support Defibrillator per Sanitari – 10 Luglio 2019
- ILS – Immediate Life Support – 4 Aprile 2013

COMPETENZE PERSONALI

Lingua madre **Italiana**

Altre lingue

Inglese

COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
Ascolto	Lettura	Interazione	Produzione orale	
C1	C1	C1	C1	C1
Livelli: A1/A2: Utente base - B1/B2: Utente intermedio - C1/C2: Utente avanzato				
<u>Quadro Comune Europeo di Riferimento delle Lingue</u>				

Patenti A, B

Competenze informatiche

Ottima conoscenza del programma statistico Stata 11 e 10.3.
Ottima conoscenza del pacchetto Microsoft Office (Word, Excel, PowerPoint, Outlook), dei browser di ricerca (Chrome, Explorer) e dei sistemi operativi (Windows 10)

Competenze comunicative

Ho sviluppato eccellenti competenze comunicative e relazionali nell'ambito dell'assistenza ai pazienti. Ho acquisito un'ottima capacità di teamwork, maturata in molteplici situazioni in cui era indispensabile la collaborazione tra differenti figure professionali.

Competenze gestionali e organizzative

Notevole organizzazione schematica e pratica.
Impostazione di un modello per migliorare la qualità dei referti endoscopici (Giugno 2017 presso UO Endoscopia della Fondazione Policlinico, Milano).
Ottima capacità di problem solving ed eccellenti capacità logiche e di adattamento.
Estrema disponibilità e senso del dovere.

Competenze formative

Per tre anni (2010-2012) ho svolto attività di tutoraggio per l'insegnamento dell'esame obiettivo e della raccolta anamnestica agli studenti del III anno di corso di Laurea in Medicina e Chirurgia, Polo San Paolo, Milano. Responsabili: Prof. M. Zuin; Prof. P. Battezzati
Attività di tutoraggio dei medici specializzandi afferenti all'UO di Gastroenterologia ed Epatologia, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico (da Agosto 2017).
Per otto anni ho preso parte attivamente all'esperienza formativa dello Scoutismo, gruppo Lovere I (BG). Socio del Club Alpino Italiano dal 2020.

Articoli Originali

1. Papatheodoridi A, Chatzigeorgiou A, Chrysavgis L, Lembessis P, **Loglio A**, Facchetti F, Cholongitas E, Koutsilieris M, Lampertico P, Papatheodoridis G. Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. *J Viral Hepat.* 2020 Dec 1. doi: 10.1111/jvh.13446. Online ahead of print.
2. Acerbi G, Montali I, Ferrigno GD, Barili V, Schivazappa S, Alfieri A, Laccabue D, **Loglio A**, Borghi M, Massari M, Rossi M, Vecchi A, Penna A, Boni C, Missale G, Lampertico P, Del Rio D, Ferrari C, Fisticaro P. Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. *J Hepatol.* 2020 Nov 11:S0168-8278(20)33751-X. doi: 10.1016/j.jhep.2020.10.034. Online ahead of print.
3. KH Peiffer, C Spengler, M Basic, B Jiang, L Kuhnhen, W Obermann, T Zahn, M Glitscher, A **Loglio**, F Facchetti, G Carra, A Kubesch, J Vermehren, V Knop, C Graf, J Dietz, F Finkelmeier, E Hermann, J Trebicka, A Grünweller, S Zeuzem, C Sarrazin, P Lampertico, E Hildt. Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. *JCI Insight.* 2020;5:135833.
4. Tham C.Y.L, Tan A.T. Kah J, Chia A, Volz T, Giersch K, Ladiges Y, **Loglio A**, Borghi M, Sureau C, Lampertico P, Lütgehetmann M, Dandri M, Bertoletti A. Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. *Cell Reports Medicine* 2020;1,100060
5. Roade L*, **Loglio A***, Borghi M, Riveiro-Barciela M, Soffredini R, Facchetti F, di Paolo D, Tabernero D, Lunghi G, Esteban R, Buti M, Lampertico P. Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. *Dig Liver Dis.* 2020;52:1164-1169 *share authorship.
6. GV Papatheodoridis, GN Dalekos, R Idilman, V Sympsa, F Van Boemmel, M Buti, JL Calleja, J Goulis, S Manolakopoulos, A **Loglio**, M Papatheodoridi, N Gatselis, R Veelken, M Lopez-Gomez, BE Hansen, S Savvidou, A Kourikou, J Vlachogiannakos, K Galanis, C Yurdaydin, R Esteban, HLA Janssen, T Berg, P Lampertico. Similar Risk of Hepatocellular Carcinoma During Long-Term Entecavir or Tenofovir Therapy in Caucasian Patients with Chronic Hepatitis B. *J Hepatol.* 2020;73:1037-1045
7. **Loglio A**, Iavarone M, Facchetti F, Di Paolo D, Perbellini R, Lunghi G, Ceriotti F, Galli C, Sandri MT, Vigano M, Sangiovanni A, Colombo M, Lampertico P. The Combination of PIVKA-II and AFP Improves the Detection Accuracy for HCC in HBV Caucasian Cirrhotics on Long-Term Oral Therapy. *Liver Int.* 2020;40:1987-1996
8. GV. Papatheodoridis, V. Sympsa, GN. Dalekos, C. Yurdaydin, F. Van Boemmel, M. Buti, JL Calleja, H. Chi, J. Goulis, S. Manolakopoulos, A. **Loglio**, T. Voulgaris, N. Gatselis, O. Keskin, R. Veelken, M. Lopez-Gomez, BE. Hansen, S. Savvidou, A. Kourikou, J. Vlachogiannakos, K. Galanis, R. Idilman, R. Esteban, H.L.A. Janssen, T. Berg, P. Lampertico. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. *J Hepatol.* 2020; 72:1088–1096
9. **Loglio A**, Lampertico P. How durable is functional cure (Hepatitis B surface antigen loss) in patients with chronic Hepatitis B treated with current antivirals? *Hepatol Commun.* 2020 Jan 2;4(1):5-7
10. Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J,

- Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; **GIANT-B Global Consortium**. Genome-wide association study identifies genetic variants associated with early and sustained response to (Pegylated) interferon in chronic hepatitis B patients: the GIANT-B study. *Clin Infect Dis*. 2019;69:1969-1979
11. **Loglio A**, Iavarone M, Viganò M, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P. Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. *Liver Int*. 2019;39:1964-1974
 12. **Loglio A**, Ferenci P, Uceda Renteria SC, Tham CYL, van Bömmel F, Borghi M, Holzmann H, Perbellini R, Trombetta E, Giovanelli S, Greco L, Porretti L, Prati D, Ceriotti F, Lunghi G, Bertolotti A, Lampertico P. Excellent safety and effectiveness of high dose myrcludex-b monotherapy administered for 48 weeks in hdv related compensated cirrhosis: a case report of three patients. *J Hepatol*. 2019;71:834-839
 13. **Loglio A**, Simone S, Lampertico P. Hepatitis d – how is the fight against this foe going? *Expert Rev Clin Pharmacol*. 2019;12:169-171
 14. Viganò M, **Loglio A**, Labanca S, Zaltron S, Castelli F, Andreone P, Messina V, Ganga R, Coppola N, Marrone A, Russello M, Marzano A, Tucci A, Taliani G, Fasano M, Fagioli S, Villa E, Bronte F, Santantonio T, Brancaccio G, Occhipinti V, Facchetti F, Grossi G, Rumi M, Lampertico P. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. *Liver Int*. 2019 Mar;39:484-493
 15. Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, **Loglio A**, Facchetti F, Lampertico P, Levrero M, Zoulim F. Serum Hepatitis B core-related antigen (HBcrAg) correlates with covalently-closed circular DNA transcriptional activity in chronic hepatitis B patients. *J Hepatol*. 2019;70:615-625
 16. Viganò M, **Loglio A**, Lampertico P. Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. *Curr Hepatology Rep*. Nov 2018. doi.org/10.1007/s11901-018-0440-8
 17. **Loglio A**, Viganò M, Grossi G, Labanca S, Goldaniga M, Pompa A, Farina L, Rumi MG, Corradini P, Facchetti F, Lunghi G, Baldini L and Lampertico P. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. *Dig Liver Dis*. 2019;51:419-424
 18. El Sharkawy R, Thabet K, Lampertico P, Petta S, Mangia A, Berg T, Metwally M, Bayoumi A, Boonstra A, Brouwer WP, Smedile A, Abate ML, **Loglio A**, Douglas MW, Khan A, Santoro R, Fischer J, Leeming DJ, Liddle C, George J, Eslam M. A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. *Aliment Pharmacol Ther*. 2018;48:564-573
 19. **Loglio A**, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. *Aliment Pharmacol Ther*. 2018;48:431-439
 20. Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, Van Boemmel F, Buti M, Goulis J, Calleja JL, C Heng, Manolakopoulos S, **Loglio A**, Siakavellas S, Gatselis N, Keskn O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P. 8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. *J Hepatol*. 2018 Jun;68:1129-1136.

21. Viganò M, Grossi G, **Loglio A**, Lampertico P. Treatment of hepatitis B: Is there still a role for interferon? Liver Int. 2018;38:79-83.
22. Viganò M, **Loglio A**, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Rev Anti Infect Ther. 2018;16:153-161
23. Grossi G, **Loglio A**, Facchetti F, Borghi M, Soffredini R, Galmozzi E, Lunghi G, Gaggari A, Lampertico P. Tenofovir Alafenamide as a rescue therapy in a cirrhotic HBV patient with a history of Fanconi Syndrome and multidrug resistance: a case report. J Hepatol. 2018; 68:195-198
24. Galmozzi E, Facchetti F, Grossi G, **Loglio A**, Viganò M, Lunghi G, Colombo M, Lampertico P. IFNL4 rs368234815 and rs117648444 variants predict off treatment HBsAg seroclearance in IFN treated HBeAg negative chronic hepatitis B patients. Liver Int. 2018;38:417-423
25. Grossi G, Viganò M, Facchetti F, Labanca S, **Loglio A**, Dodero A, Montefusco V, Corradini P, Cafro A, Cairoli R, Colombo M, Lampertico P. Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogeneic hematopoietic stem cell transplantation for hematological malignancies: two case reports. Haematologica. 2017;102:e423-e426.
26. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, **Loglio A**, Siakavelas S, Keskin O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444-1453
27. Grossi G, Viganò M, **Loglio A**, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleos(t)ide analogues (NUCs). Liver Int. 2017;37:45-51
28. Lampertico P, Invernizzi F, Viganò M, **Loglio A**, Mangia G, Facchetti F, Primignani M, Jovani M, Iavarone M, Fraquelli M, Casazza G, de Franchis R, Colombo M. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. J Hepatol. 2015; 63:1118-25

**Abstract presentati come
Comunicazioni Orali**

1. **A. Loglio**, A. Alexandrov, S.C. Uceda Renteria, C.Y.L. Tham, L. Greco, M. Borghi, R. Perbellini, E. Trombetta, S. Giovanelli, L. Porretti, L. Lecchi, D. Prati, F. Ceriotti, G. Lunghi, A. Bertolotti, P. Lampertico. Safety, effectiveness and T-cell activation profiles of long-term Mycludex-B treatment in two patients with HDV related compensated cirrhosis. Oral presentation. APASL HDV Meeting, 27 Giugno 2019, Baku. Conference Abstract Book
2. **A. Loglio**, S.C. Uceda Renteria, L. Greco, E. Farina, E. Filippi, G. Lunghi, F. Ceriotti, P. Lampertico. Comparison of three HDV-RNA quantitative commercially available tests in untreated and in Mycludex-B treated patients with HDV related chronic hepatitis in a real-life setting. Oral presentation. APASL HDV Meeting, 27 Giugno 2019, Baku. Conference Abstract Book
3. **A. Loglio**, F. Facchetti, C. Orsini, A. Perego, R. Perbellini, S.C. Uceda Renteria, S. Segato, G. Lunghi, F. Ceriotti, P. Lampertico. Quantitative antibodies against hepatitis B core antigen differ in NUC suppressed caucasian HBeAG-negative patients compared to patients who achieved either “NUC induced” or “spontaneous” functional cure of HBV. Oral presentation. EASL ILC Meeting, 11 Aprile 2019, Vienna. J Hepatol 2019; 70:33
4. **A. Loglio**, L. Roade, M. Borghi, R. Soffredini, F. Facchetti, D. Di Paolo, M. Riveiro Barciela,

D. Tabernero, G. Lunghi, M. Buti and P. Lampertico. Validation of the EASL 2017 Clinical Practice Guidelines Criteria for switching HBV patients long-term treated with TDF to ETV or TAF. Oral presentation. AASLD The Liver Meeting, 12 Novembre 2018, San Francisco. HEPATOLOGY 2018, 68:165A-166A

5. M. Iavarone, **A. Loglio**, G. Grossi, M. Viganò, F. Facchetti, M.G. Rumi, A. Sangiovanni, P. Lampertico. Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment. Oral presentation. 51° Riunione Generale Annuale AISEF, Roma, 23 Febbraio 2018. Digestive and Liver Disease 2018, 50:11

Relatore a Convegni

1. "Effectiveness, safety and histological improvement of long-term administration of 10 mg/day MYR-B for HDV hepatitis: a case report of 3 patients", 18th Hepatitis Delta International Network (HDIN). Sheraton Hotel, Boston (MA). 9 Novembre 2019
2. "Insights into novel therapeutic options for the treatment of HDV infection" all'interno del Simposio "Un espoir pour la guérison du delta", AFEF 2019 Congress, Palais du Pharo, Marseille (FR). 2 Ottobre 2019
3. "HDV and Autoimmunity", Hepatitis Masterclass 2019, Le Village by CA, Milano. 27 Settembre 2019
4. "NUC and HCC risk". Hepatitis Masterclass 2018, Rosa Grand Hotel, Milano. 28 Settembre 2018
5. "Ruolo del dosaggio dell'alfa-fetoproteina nel predire lo sviluppo di epatocarcinoma nei pazienti cirrotici HBV: studio di coorte in 262 soggetti trattati con analoghi nucleos(t)idici per otto anni". Giornata dello Specializzando 2017 in Malattie dell'apparato digerente", Milano. 16 Ottobre 2017

Abstracts presentati come poster o e-poster

1. **A. Loglio**, P. Ferenci, H. Holzmann, SC. Uceda Renteria, M. Borghi, R. Perbellini, A. Rimondi, E. Trombetta, S. Giovanelli, L. Porretti, D. Prati, F. Ceriotti, G. Lunghi, P. Lampertico. Myrcludex monotherapy in compensated cirrhotics with Delta hepatitis: safety and effectiveness beyond two years of treatment in a real-life setting. HEPATOLOGY 2020; 72:624A
2. P. Fisicaro, I. Montali, G. Acerbi, V. Barili, **A. Loglio**, S. Schivazappa, F. Brillo, A. Penna, D. Laccabue, M. Rossi, A. Vecchi, M. Massari, C. Boarini, G. Abbati, C. Boni, G. Missale, S. Ottonello, P. Lampertico, C. Ferrari. Correction of dysregulated intracellular signaling pathways by NAD pool reconstitution can restore anti-viral HBV-specific T cell responses in chronic hepatitis B. HEPATOLOGY 2020; 72:512A
3. C. Boni, M. Rossi, A. Vecchi, V. Barili, C. Tiezzi, P. Fisicaro, I. Montali, S. Daffis, S. Fletcher, A. Gaggari, **A. Loglio**, A. Alfieri, F. Brillo, D. Laccabue, M. Massari, C. Boarini, G. Abbati, G. Missale, P. Lampertico, C. Ferrari. Characterization of CD8 T cell heterogeneity in chronic HBV infection by functional/phenotypic profiling to predict the effect of immune modulation on the CD8 T cell function. HEPATOLOGY 2020; 72:509A
4. **A. Loglio**, M. Viganò, M. Borghi, C. Gentile, F. Facchetti, R. Perbellini, R. Soffredini, G. Lunghi, MG. Rumi, P. Lampertico. Early changes of proximal tubular markers in CHB patients switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide according to EASL 2017 criteria: a real-life study. HEPATOLOGY 2020; 72:481-482A
5. ML. Plissonnier, F. Guerrieri, **A. Loglio**, F. Facchetti, CC. de Fromentel, P. Lampertico, M. Zeisel, M. Levrero. Circulating microRNAs to identify hepatocellular carcinoma risk in patients with hepatitis B virus related cirrhosis treated with nucleot(s)ide analogues. HEPATOLOGY 2020; 72:439-440A
6. B. Testoni, C. Scholtès, ML. Plissonnier, F. Berby, F. Facchetti, F. Villeret, **A. Loglio**, B. Scott, L. Wang, A. Hamilton, M. Heil, P. Lampertico, M. Levrero, F. Zoulim. Circulating HBV RNA correlates with intrahepatic covalently closed circular DNA (cccDNA) levels and activity in

untreated chronic hepatitis B (CHB) patients. HEPATOLOGY 2020; 72:438A

7. E. Farina, **A. Loglio**, G. Tosetti, M. Viganò, C. Gentile, R. Perbellini, M. Borghi, F. Facchetti, G. Lunghi, MG. Rumi, M. Primignani, P. Lampertico. Long-term treatment with Tenofovir or Entecavir could spare endoscopic surveillance of esophageal varices in HBV compensated cirrhotics: a 10-year study. HEPATOLOGY 2020; 72:465-466A
8. ML. Plissonnier, **A. Loglio**, F. Guerrieri, F. Facchetti, CC. de Fromentel, M. Zeisel, P. Lampertico, M. Levrero. Circulating microRNAs profiles to predict the risk of HCC development in DAA-treated HCV-related cirrhosis. HEPATOLOGY 2020; 72:33°
9. **A. Loglio**, P. Ferenci, F. Schlund, C.Y.L. Tham, F. van Bommel, SC. Uceda Renteria, M. Borghi, H. Holzmann, R. Perbellini, E. Trombetta, S. Giovanelli, L. Porretti, D. Prati, F. Ceriotti, G. Lunghi, A. Bertolotti, S. Urban, P. Lampertico. Safety and efficacy of up to 76 weeks 10 mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis. J Hepatol 2020; 73:S861-862
10. **A. Loglio**, F. Facchetti, E. Farina, N. Nandi, A. Perego, R. Perbellini, SC. Uceda Renteria, M. Borghi, R. Soffredini, C. Orsini, G. Lunghi, F. Ceriotti, P. Lampertico. Correlation between HBV core-related antigen and the new quantitative IgG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure. J Hepatol 2020; 73:S862
11. ML. Plissonnier, **A. Loglio**, F. Guerrieri, F. Facchetti, CC. de Fromentel, M. Zeisel, P. Lampertico, M. Levrero. Identification of circulating microRNAs predictive of HCC in DAA cured HCV-related cirrhosis. J Hepatol 2020; 73:S617-618
12. E. Galmozzi, **A. Loglio**, F. Facchetti, M. Iavarone, M. Borghi, M. Viganò, R. Perbellini, MG. Rumi, A. Sangiovanni, P. Lampertico. Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years. J Hepatol 2020; 73:S586
13. A.M. Papatheodoridi, A. Chatzigeorgiou, L. Chrysavgis, P. Lembessis, **A. Loglio**, F. Facchetti, E. Cholongitis, M. Koutsilieris, P. Lampertico, G. Papatheodoridis. Serum levels of circulating DNA species can predict the development of hepatocellular carcinoma in chronic hepatitis B patients under long-term oral antiviral therapy. J Hepatol 2020; 73:S581-582
14. G. Papatheodoridis, G. Dalekos, R. Idilman, V. Sypsa, F. van Bömmel, M. Buti, JL. Calleja Panero, I. Goulis, S. Manolakopoulos, **A. Loglio**, M. Papatheodoridi, N. Gatselis, R. Veelken, M. López-Gómez, B. Hansen, S. Savvidou, A. Kourikou, I. Vlachogiannakos, K. Galanis, C. Yurdaydin, R. Esteban, H. Janssen, T. Berg, P. Lampertico. PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy. J Hepatol 2020; 73:S586-587
15. **A. Loglio**, F. Schlund, C.Y.L. Tham, F. van Bömmel, P. Ferenci, S.C. Uceda Renteria, M. Borghi, H. Holzmann, R. Perbellini, E. Trombetta, S. Giovanelli, L. Porretti, D. Prati, F. Ceriotti, G. Lunghi, A. Alexandrov, A. Bertolotti, S. Urban, P. Lampertico. Safety and efficacy of up to 76 weeks 10 mg/day (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis. Digestive and Liver Disease 2020; 52:28-29
16. M. Viganò, **A. Loglio**, F. Cerini, E. Farina, F. Facchetti, R. Perbellini, M.G. Rumi, P. Lampertico. Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients. Digestive and Liver Disease 2020; 52:27
17. E. Galmozzi, **A. Loglio**, F. Facchetti, M. Iavarone, M. Borghi, M. Viganò, R. Perbellini, M.G. Rumi, A. Sangiovanni, P. Lampertico. Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated hbv cirrhotics treated with nuc for 10 years. Digestive and Liver Disease 2020;

18. 10. **A. Loglio**, F. Schlund, C.Y.L. Tham, F. van Bömmel, P. Ferenci, S.C. Uceda Renteria, M. Borghi, H. Holzmann, R. Perbellini, E. Trombetta, S. Giovanelli, L. Porretti, D. Prati, F. Ceriotti, G. Lunghi, A. Alexandrov, A. Bertoletti, S. Urban, P. Lampertico. Long-term administration of 10 mg/day Myrcludex-B monotherapy in patients with HDV related compensated cirrhosis in a real-life setting: effectiveness, safety and virus to host interactions. HEPATOLOGY 2019;70(1):633
19. **A. Loglio**, F. Facchetti, E. Farina, A. Perego, R. Perbellini, S.C. Uceda Renteria, M. Borghi, R. Soffredini, N. Nandi, M. Pedaci, C. Orsini, G. Lunghi, F. Ceriotti, P. Lampertico. Quantitative assessment of IgG antibodies against Hepatitis B Core Antigen in Caucasian HBeAg-negative patients long-term NUC treated, with and without functional cure. HEPATOLOGY 2019;70(1):625
20. F. van Bömmel, **A. Loglio**, D. Deichsel, F. Facchetti, T. Berg, P. Lampertico. HBV RNA decreases to undetectable levels in most HBeAg negative patients during treatment with Tenofovir or Entecavir up to 14 years. HEPATOLOGY 2019;70(1):421
21. M. Iavarone, **A. Loglio**, E. Degasper, R. D'Ambrosio, F. Facchetti, A. De Monti, D. Di Paolo, R. Perbellini, M. Bruccoleri, G. Lunghi, F. Ceriotti, C. Galli, A. Perego, M.T. Sandri, M. Viganò, A. Sangiovanni, M. Colombo, P. Lampertico. PIVKA_{II} is a useful biomarker for the diagnosis and management of HCC developing in caucasian patients with HBV- and HCV-related cirrhosis without viral replication. HEPATOLOGY 2019;70(1):1212
22. G.V. Papatheodoridis, G.N. Dalekos, C. Yurdaydin, V. Sypsa, F. van Bömmel, M. Buti, J.L. Calleja, I. Goulis, S. Manolakopoulos, **A. Loglio**, M. Papatheodoridi, N.K. Gatselis, O. Keskin, R. Veelken, M. Lopez Gomez, B. Hansen, S. Savvidou, A. Kourikou, J. Vlachogiannakos, K. Galanis, R. Idilman, R.E. Esteban-Mur, H.L.A. Janssen, T. Berg, P. Lampertico. Similar risk of hepatocellular carcinoma (HCC) development during long-term entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Caucasian Chronic Hepatitis B (CHB) patients. HEPATOLOGY 2019;70(1):286
23. G. Tosetti, **A. Loglio**, E. Degasper, R. D'Ambrosio, M. Viganò, M. Iavarone, M. Borghi, R. Soffredini, F. Facchetti, M.G. Rumi, M. Primignani, P. Lampertico. Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study. J Hepatol 2019; 70:687-688
24. F. van Bömmel, D. Deichsel, **A. Loglio**, F. Facchetti, M. Pfefferkorn, M. Brehm, T. Berg, P. Lampertico. HBV RNA can be detected more frequently than HBcAg but decreases during long term treatment with nucleos(t)ide analogues up to 14 years in patients with HBeAg negative chronic hepatitis B. J Hepatol 2019; 70:487
25. S. Uceda, L. Greco, **A. Loglio**, G. Lunghi, P. Lampertico. Xpert HBV VL, simplifying HBV viral load testing and disease management. J Hepatol 2019; 70:262
26. G. Papatheodoridis, G. Dalekos, C. Yurdaydin, V. Sypsa, F. van Bommel, M. Buti, J.L. Calleja Panero, H. Chi, I. Goulis, S. Manolakopoulos, **A. Loglio**, T. Voulgaris, N. Gatselis, O. Keskin, R. Veelken, M. Lopez-Gomez, B. Hansen, S. Savvidou, A. Kourikou, I. Vlachogiannakos, K. Galanis, R. Idilman, R. Esteban, H. Janssen, T. Berg, P. Lampertico. Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients. J Hepatol 2019; 70:477-478
27. C. Y.L. Tham, J. Kah, A. Tan, **A. Loglio**, C. Sureau, M. Lütgehetmann, P. Lampertico, M. Dandri, A. Bertoletti. HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy. J Hepatol 2019; 70:51 Oral Presentation at EASL 2019
28. **A. Loglio**, A. Alexandrov, S.C. Uceda Renteria, C.Y.L. Tham, L. Greco, M. Borghi, R. Perbellini, E. Trombetta, S. Giovanelli, L. Porretti, L. Lecchi, D. Prati, F. Ceriotti, G. Lunghi, A. Bertoletti, P.

- Lampertico. Effectiveness, safety and T-cell activation profiles of long-term Myrcludex B treatment in two patients with HDV related compensated cirrhosis. Digestive and Liver Disease 2019; 51:62
29. **A. Loglio**, E. Galmozzi, M. Iavarone, F. Facchetti, M. Viganò, R. Perbellini, S. Segato, E. Filippi, M.G. Rumi, A. Sangiovanni, P. Lampertico. The development of hepatocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 10 years. Digestive and Liver Disease 2019; 51:56
 30. G. Tosetti, **A. Loglio**, E. Degasperri, R. D'Ambrosio, M. Viganò, M. Iavarone, M. Borghi, R. Soffredini, F. Facchetti, M.G. Rumi, M. Primignani, P. Lampertico. Incidence and outcome of portal vein thrombosis in 817 HBV and HCV cirrhotic patients under antiviral treatment: a single center longitudinal study. Digestive and Liver Disease 2019; 51:10
 31. **A. Loglio**, M. Iavarone, F. Facchetti, D. Di Paolo, R. Perbellini, G. Lunghi, C. Galli, M.T. Sandri, A. Sangiovanni and P. Lampertico. The Combination of Pivka-II and AFP Levels Improves the Diagnostic Accuracy of HCC Diagnosis in Long-Term NUC Suppressed HBV Caucasian Cirrhotics. HEPATOLOGY 2018; 68:S517
 32. **A. Loglio**, E. Galmozzi, M. Iavarone, F. Facchetti, M. Viganò, R. Perbellini, D. Di Paolo, R. Bertè, M. Franchina, M.G. Rumi, A. Sangiovanni and P. Lampertico. Genetic Variants Do Not Predict the Development of Hepatocellular Carcinoma in Caucasian Compensated HBV Cirrhotics Long-Term Treated by Entecavir or Tenofovir. HEPATOLOGY 2018; 68:S1215-1216
 33. F. van Bömmel, D. Deichsel, **A. Loglio**, F. Facchetti, T. Berg and P. Lampertico, HBV RNA Can Still be Quantified in Serum in HBeAg Negative Patients after Suppression of HBV DNA By Nuleos(t)ide Analogues for up to 10 Years. HEPATOLOGY 2018; 68:S273-274
 34. M. Brunetto, I. Carey, B. Maasoumy, C. Marcos, G. Van Halewijn, G. Caviglia, **A. Loglio**, D. Cavallone, C. Scholtes, A. Smedile, M. Riveiro-Barciela, F. van Bömmel, A. Van Der Eijk, F. Zoulim, T. Berg, M. Cornberg, P. Lampertico, K. Agarwal and M. Buti. Hepatitis B Core-Related Antigen Is a Better Marker Than HBsAg for Discriminating between Chronic HBV Infection and Chronic Hepatitis B in a HBeAg-negative European Cohort. HEPATOLOGY 2018; 68:S1183-1184
 35. G.V. Papatheodoridis, G. Dalekos, C. Yurdaydin, V. Sypsa, F. van Bömmel, M. Buti, J. Calleja, H. Chi, I. Goulis, S. Manolakopoulos, **A. Loglio**, S. Siakavellas, N. Gatselis, O. Keskin, R. Veelken, M. Lopez-Gomez, B. Hansen, S. Savvidou, A. Kourikou, I. Vlachogiannakos, K. Galanis, R. Idilman, R. Esteban, H. Janssen, T. Berg and P. Lampertico. Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF) therapy in caucasian chronic hepatitis B (CHB) patients of the PAGE-B cohort. HEPATOLOGY 2018; 68:S11-12. Oral communication at AASLD
 36. G.V. Papatheodoridis, G. Dalekos, C. Yurdaydin, V. Sypsa, F. van Bömmel, M. Buti, J. Calleja, H. Chi, I. Goulis, S. Manolakopoulos, **A. Loglio**, S. Siakavellas, N. Gatselis, O. Keskin, R. Veelken, M. Lopez-Gomez, B. Hansen, S. Savvidou, A. Kourikou, I. Vlachogiannakos, K. Galanis, R. Idilman, R. Esteban, H. Janssen, T. Berg and P. Lampertico. ALT Levels and risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term therapy with Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF). HEPATOLOGY 2018; 68:S162-163. Oral communication at AASLD
 37. **A. Loglio**, G. Tosetti, G. Grossi, M. Iavarone, M. Viganò, F. Facchetti, M. Rumi, A. Sangiovanni, M. Primignani, P. Lampertico. The long-term risk and outcome of non-neoplastic portal vein thrombosis developing in compensated caucasian HBV cirrhotics treated with Tenofovir or Entecavir. J Hepatol 2018; 68:S521-S522
 38. **A. Loglio**, E. Galmozzi, M. Iavarone, G. Grossi, M. Viganò, F. Facchetti, M.G. Rumi, A. Sangiovanni, P. Lampertico. Clinical and genetic predictors of HCC occurring in caucasian

- compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. J Hepatol 2018; 68: S521-S522
39. **A. Loglio**, G. Grossi, R. Soffredini, M. Borghi, F. Facchetti, E. Galmozzi, G. Lunghi, P. Lampertico. Validation of the EASL 2017 HBV clinical practice guidelines criteria for switching patients long-term treated with Tenofovir difumarate to Entecavir or Tenofovir alafenamide in a real life setting. J Hepatol 2018; 68:S521
 40. **A. Loglio**, M. Iavarone, F. Facchetti, G. Grossi, E. Galmozzi, R. Perbellini, G. Lunghi, C. Galli, MT. Sandri, A. Sangiovanni, P. Lampertico. The combination of PIVKA-II and AFP levels improves the diagnostic accuracy of HCC developing in long-term NUC suppressed HBV Caucasian cirrhotics. P07-07, Abstract book of EASL HCC Summit, 1-3 March 2018
 41. **A. Loglio**, E. Galmozzi, M. Iavarone, G. Grossi, M. Viganò, F. Facchetti, MG Rumi, R. Perbellini, A. Sangiovanni, P. Lampertico. Clinical and genetic predictors of HCC occurring in Caucasian compensated HBV cirrhotics treated by entecavir or tenofovir for 8 years. P06-07, Abstract book of EASL HCC Summit, 1-3 March 2018
 42. M. Iavarone, **A. Loglio**, G. Grossi, M. Viganò, F. Facchetti, M.G. Rumi, R. Perbellini, A. Sangiovanni, P. Lampertico. Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment. P06-10, Abstract book of EASL HCC Summit, 1-3 March 2018
 43. **A. Loglio**, E. Galmozzi, M. Iavarone, G. Grossi, M. Viganò, F. Facchetti, R. Perbellini, MG Rumi, A. Sangiovanni, P. Lampertico. Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. Digestive and Liver Disease 2018; 50:51
 44. **A. Loglio**, G. Grossi, R. Soffredini, M. Borghi, F. Facchetti, E. Galmozzi, R. Perbellini, G. Lunghi, P. Lampertico. Validation of the EASL 2017 HBV Clinical Practice Guidelines criteria for switching patients long-term treated with Tenofovir Difumarate to Entecavir or Tenofovir Alafenamide in a real-life setting. Digestive and Liver Disease 2018; 50:55
 45. **A. Loglio**, G. Grossi, M. Viganò, M. Iavarone, F. Facchetti, A. Perroni, M. Primignani, A. Sangiovanni, P. Lampertico. Minimal increases of alpha-fetoprotein strongly predict HCC development in Caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: a 8-year longitudinal cohort study in 262 patients – final results. HEPATOLOGY 2017; 66:993A
 46. **A. Loglio**, G. Grossi, M. Iavarone, M. Viganò, A. Sangiovanni, M. Colombo, P. Lampertico. Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients. J Hepatol 2017; 66: S689 *Presentazione orale dell'e-poster a EASL 2017*
 47. P. Lampertico, G. Grossi, **A. Loglio**, F. Facchetti, E. Galmozzi, M. Colombo. High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients. J Hepatol 2017; 66:S689
 48. E. Galmozzi, F. Facchetti, G. Grossi, **A. Loglio**, M. Colombo, P. Lampertico. Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B. J Hepatol 2017; vol 66, page S261
 49. **A. Loglio**, G. Grossi, M. Iavarone, M. Viganò, A. Sangiovanni, M. Colombo, P. Lampertico. Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: A 7-year longitudinal cohort study in 225 patients. Digestive and Liver Disease 2017; 49:e28. *Poster con coccarda al 50° meeting AISF 2017*
 50. G. Grossi, R. Soffredini, M. Borghi, **A. Loglio**, F. Facchetti, E. Galmozzi, P. Lampertico Renal

- tubular damage worsens over time in HBV monoinfected patients long-term treated with tenofovir: a prospective, single center, real-life study in 391 patients. AASLD 2017, HEPATOLOGY 2017; 66: 1028A-1029A
51. M. Viganò, G. Grossi, S. Labanca, **A. Loglio**, MG. Rumi, P. Lampertico. High rates of osteopenia and osteoporosis in chronic hepatitis B caucasian patients untreated and treated with tenofovir disoproxil fumarate (TDF): a 4-year longitudinal cohort study. HEPATOLOGY 2017; 66: 797A
 52. G. Grossi, **A. Loglio**, F. Facchetti, E. Galmozzi, M. Colombo, P. Lampertico. High rates of renal tubular damage in HBV monoinfected patients long-term treated with tenofovir: A cross-sectional, single center, real-life study in 414 patients, Digestive and Liver Disease 2017; 49:e9
 53. M. Viganò, G. Grossi, **A. Loglio**, M. Cappelletti, S. Zaltron, F. Castelli, P. Andreone, V. Messina, R. Ganga, N. Coppola, A. Marrone, M. Russello, A. Marzano, G. Taliani, M. Fasano, S. Fagioli, E. Villa, F. Bronte, T. Santantonio, G. Brancaccio, F. Facchetti, P. Lampertico. Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients. Digestive and Liver Disease 2017; 49:e37
 54. E. Galmozzi, F. Facchetti, G. Grossi, **A. Loglio**, P. Lampertico. Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B. Digestive and Liver Disease 2017; 49:e29
 55. G. Grossi, **A. Loglio**, M. Viganò, M. Cappelletti, MC. Goldaniga, L. Farina, MG. Rumi, P. Corradini, L. Baldini, M. Colombo, P. Lampertico. Universal prophylaxis with lamivudine prevents hepatitis B reactivation in HBsAg-negative/anti-HBc positive patients undergoing rituximab-based chemotherapy for non-Hodgkin B cell lymphoma – final results. HEPATOLOGY 2016; Vol 64, NUMBER 1 (suppl), page 888A
 56. M. Viganò, **A. Loglio**, M. Cappelletti, S. Zaltron, F. Castelli, P. Andreone, V. Messina, R. Ganga, N. Coppola, A. Marrone, M. Russello, A. Marzano, G. Taliani, M. Fasano, S. Fagioli, E. Villa, F. Bronte, T. Santantonio, G. Brancaccio, F. Facchetti, P. Lampertico. Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients. HEPATOLOGY 2016; Vol 64, NUMBER 1 (suppl), page 37A
 57. E. Galmozzi, P. Lampertico, F. Facchetti, F. Invernizzi, G. Grossi, **A. Loglio**, M. Viganò, M. Colombo. STAT4 rs7574865 polymorphism does not predict HBsAg loss in IFN treated genotype D HBeAg-negative patients with chronic Hepatitis B. HEPATOLOGY 2016; Vol 64, NUMBER 1 (suppl), page 886A
 58. GV. Papatheodoridis, C. Yurdaydin, GN. Dalekos, M. Buti, H. Chi, F. van Bömmel, JL. Calleja, V. Sypsa, I. Goulis, S. Manolakopoulos, **A. Loglio**, SI. Siakavellas, O. Keskin, N. Gatselis, BE. Hansen, M. Lehtretz, J. de la Revilla, S. Savvidou, A. Kourikou, J. Vlachogiannakos, R. Idilman, K. Galanis, T. Berg, M. Colombo, R. Esteban, HL. Janssen, Pietro Lampertico. The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. HEPATOLOGY 2016; Vol 64, NUMBER 1 (suppl), page 923A
 59. GV. Papatheodoridis, GN. Dalekos, C. Yurdaydin, F. van Bömmel, M. Buti, V. Sypsa, J. Goulis, JL. Calleja, H. Chi, S. Manolakopoulos, **A. Loglio**, N. Gatselis, O. Keskin, M. Lehtretz, S. Savvidou, J. de la Revilla, BE. Hansen, J. Vlachogiannakos, K. Galanis, R. Idilman, M. Colombo, R. Esteban, HL. Janssen, T. Berg, P. Lampertico. Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under longterm entecavir (ETV) or tenofovir (TDF) therapy. HEPATOLOGY 2016; Vol 64, NUMBER 1 (suppl), page 35A
 60. P. Lampertico, G. Grossi, **A. Loglio**, M. Viganò, F. Facchetti, F. Invernizzi, M. Iavarone, A.

Sangiovanni, M. Colombo. Hepatocellular carcinoma developing in European patients with prolonged HBV suppression: Biological and clinical features, and outcome. Digestive and Liver Disease, Volume 48, Supplement 1, 10 February 2016, Pages e48-e49

61. M. Viganò, P. Lampertico, R. Soffredini, F. Invernizzi, **A. Loglio**, F. Facchetti, M. Colombo. Switching to tenofovir is safe in most CHB patients with a reduced glomerular filtration rate due to previous exposure to adefovir dipivoxil. Digestive and Liver Disease, Volume 45, Supplement 1, February 2013, Page S35
62. F. Invernizzi, P. Lampertico, G. Mangia, R. Soffredini, F. Facchetti, **A. Loglio**, G. Lunghi, M. Colombo. Add-on Peg-IFN improves HBsAg kinetics in HBeAg-negative patients long-term fully suppressed by nucleos(t)ide analogs. Digestive and Liver Disease, Volume 45, Supplement 1, February 2013, Page S19
63. F. Invernizzi, P. Lampertico, **A. Loglio**, M. Iavarone, et al. Nucleos(t)ide analogues can be safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance. Hepatology 2012; Vol 56, 4 (suppl), page 368A

Impact factor e Reviewer

h-Index: 10; i10-Index: 10; citazioni: 509 (dal 2015, fonte Google Scholar); RG score: 36.86 (ResearchGate.net).

ORCID 0000-0001-8022-8803

Reviewer per le seguenti riviste scientifiche: Journal of Hepatology, Liver International, Digestive and Liver Disease, PlosOne.

Studi in Good Clinical Practice (GCP) e collaborazioni scientifiche

Dal 2014 ad oggi ho preso parte attivamente come Sub-investigatore ad almeno 15 GCP therapeutical trials in fase II e III nella ricerca HBV (HERMES, GIANT, GS-1848, GS-1059, GS-1508, ImmunoPeg, GS-1062, GS-4018, GS-4035, JNJ-56136379HPB2001, 73763989HPB2001 REEF-1, 73763989HPB2002 REEF-2, GSK-209668 B-Clear) ed HDV (EIG-LNF-011, MYR 301) ed osservazionali (PITER-HBV/HDV, CirB-RNA).

Nell'ambito della ricerca HBV/HDV/HCC collaboro con i gruppi italiani (Prof. Ferrari) ed internazionali (Prof. Papatheodoridis, Prof. Zoulim, Prof.ssa Buti, Prof. Levrero, Prof. Bertolotti, Prof. Van Boemmel).

Membro di Società Scientifiche

HDIN (Hepatitis Delta International Network) dal 2018
EASL (European Association for the Study of the Liver) dal 2018
AISF (Associazione Italiana per lo Studio del Fegato) dal 2016
SIUMB (Società Italiana di Ultrasonologia in Medicina e Biologia) dal 2016

Autorizzo il trattamento dei miei dati personali come previsto dal D.Lvo 30.6.2003, nr. 196 e del Regolamento UE 2016/679 del 27.4.2016 (GDPR – General Data Protection Regulation) sulla privacy.

Autorizzo il trattamento dei dati per la pubblicazione sul sito web della Fondazione, ai sensi della normativa vigente ed in particolare dell'articolo 15 del d.lgs. n. 33 del 14 marzo 2013.

Il presente curriculum ha la funzione di autocertificazione ai sensi del D.P.R. 445/2000.

Milano, 27 Dicembre 2020